Bone, inflammation, and inflammatory bowel disease

被引：60

作者：

Agrawal M. ^{[1
]}

Arora S. ^{[2
]}

Li J. ^{[1
]}

Rahmani R. ^{[1
]}

Sun L. ^{[3
]}

Steinlauf A.F. ^{[4
]}

Mechanick J.I. ^{[3
]}

Zaidi M. ^{[3
]}

机构：

[1] Department of Gastroenterology, Maimonides Medical Center, Brooklyn, NY 11201

[2] Department of Internal Medicine, Wyckoff Heights Medical Center, Affiliate of Weill Cornell Medical College, Brooklyn, NY

[3] Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, NY

[4] Department of Gastroenterology, Mount Sinai School of Medicine, New York, NY

来源：

Current Osteoporosis Reports | 2011年 / 9卷 / 4期

关键词：

Bone; Bone loss; Cytokines; Inflammation; Inflammatory bowel disease; Osteoblast; Osteoclast;

D O I：

10.1007/s11914-011-0077-9

中图分类号：

学科分类号：

摘要：

Osteoporosis is a leading cause of morbidity in patients with inflammatory bowel disease (IBD). Bone loss is an early systemic process and occurs even before clinical disease manifests. Bone disease is attributed to vitamin D deficiency, steroid use, and/or systemic inflammation. In this review, we discuss the molecular pathways of bone loss mediated by inflammatory cytokines and other mediators. Further research will hopefully clarify the mechanisms of inflammation-induced bone loss in IBD and guide effective treatment modalities. © 2011 Springer Science+Business Media, LLC.

引用

页码：251 / 257

页数：6

共 57 条

[21]

Mahida Y.R., Wu K., Jewell D.P., Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease, Gut, 30, 6, pp. 835-838, (1989)

[22]

Nemetz A., Toth M., Garcia-Gonzalez M.A., Zagoni T., Feher J., Pena A.S., Tulassay Z., Allelic variation at the interleukin 1 β gene is associated with decreased bone mass in patients with inflammatory bowel diseases, Gut, 49, 5, pp. 644-649, (2001)

[23]

Kusugami K., Et al., Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent, Dig Dis Sci, 40, 5, pp. 949-59, (1995)

[24]

Shen C., Landers C.J., Derkowski C., Elson C.O., Targan S.R., Enhanced CBir1- specific innate and adaptive immune responses in Crohn's disease, Inflamm Bowel Dis, 14, 12, pp. 1641-51, (2008)

[25]

Targan S.R., Landers C.J., Yang H., Lodes M.J., Cong Y., Papadakis K.A., Vasiliauskas E., Elson C.O., Hershberg R.M., Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease, Gastroenterology, 128, 7, pp. 2020-2028, (2005)

[26]

Axmann R., Bohm C., Kronke G., Zwerina J., Smolen J., Schett G., Inhibition of interleukin-6 receptor directly blocks OC formation in vitro and in vivo, Arthritis Rheum, 60, 9, pp. 2747-56, (2009)

[27]

Garnero P., Thompson E., Woodworth T., Smolen J.S., Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone, Arthritis Rheum, 62, 1, pp. 33-43, (2010)

[28]

Li J., Sarosi I., Yan X.-Q., Morony S., Capparelli C., Tan H.-L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S.-C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C.R., Lacey D.L., Boyle W.J., RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism, Proceedings of the National Academy of Sciences of the United States of America, 97, 4, pp. 1

[29]

Fuller K., Murphy C., Kirstein B., Fox S.W., Chambers T.J., TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL, Endocrinology, 143, 3, pp. 1108-1118, (2002)

[30]

Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L., TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand, Journal of Clinical Investigation, 106, 12, pp. 1481-1488, (2000)

← 1 2 3 4 5 6 →